Alcon is the global leader in eye care, dedicated to helping people see brilliantly.
Alcon offers the widest spectrum of eye care products in surgical, pharmaceutical and vision care. We operate in more than 75 countries, serve 180 markets and employ over 25,000 people from all walks of life.
We offer the industry’s most complete line of ophthalmic surgical products, enabling surgeons to achieve the best results for their patients. Our surgical portfolio includes technologies and devices for cataract, retinal, refractive surgery, as well as advanced technology intraocular lenses to treat cataracts and refractive errors, like presbyopia and astigmatism. We also provide advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery.
Alcon has a strong commitment to its partnership with eye care professionals and humanitarian organisations locally and internationally. We regularly embark on medical missions focused on correcting preventable blindness around the world. We also support local initiatives in Australia that support rural and remote communities to achieve better eye health outcomes.
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.
Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018.
In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions.
Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
After years of professional training to become a qualified specialist its vital that Ophthalmologists get the right advice to protect their future income potential. Let Legacy help evaluate the best options for you.
Legacy would like to offer a free, no obligation, review of your insurance needs - business and professional.
Please see our website for details of our services: http://www.legacygroup.co.nz/ and contact Simon Rupapera for a confidential discussion - DDI 09 354 5500,
M 021 895 114 E email@example.com